Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)

March 13, 2024 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)

The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This study is testing a medication, called hydroxychloroquine (HCQ) to assess safety and effectiveness to prevent individuals at risk of type 1 diabetes (T1D) from progressing to type 1 diabetes.

HCQ is approved by the U.S. Food and Drug Administration as a treatment for malaria, lupus, and rheumatoid arthritis. HCQ has been used extensively for treatment of autoimmune disease in adults, children, and during pregnancy. This medication has not previously been studied as a treatment to prevent T1D.

The goal of this study is to learn if HCQ can help prevent or delay progression from normal glucose tolerance (Stage 1) to abnormal glucose tolerance (Stage 2) or type 1 diabetes (Stage 3).

The study involves 5 visits in the first 6 months, then 1 visit every 6 months for the remainder of the study.

Study Type

Interventional

Enrollment (Actual)

273

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • St. Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital
    • South Australia
      • North Adelaide, South Australia, Australia, 5006
        • Women's and Children's Hospital, Adelaide
    • Victoria
      • Parkville, Victoria, Australia, 3052
        • Walter and Eliza Hall Institute of Medical Research
    • Western Australia
      • Perth, Western Australia, Australia, 6840
        • Perth Children's Hospital
  • Canada
      • Halifax, Canada, NS B3K 6R8
        • IWK Health Center
    • Ontario
      • Ottawa, Ontario, Canada, K1H8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Canada, M5G-1X8
        • The Hospital for Sick Kids
  • Italy
      • Milan, Italy, 20132
        • San Raffaele Hospital
  • Sweden
      • Malmö, Sweden, 20502
        • Skane University Hospital
  • United Kingdom
      • Nottingham, United Kingdom, NG7 2UH
        • Nottingham University Hospitals
    • Devon
      • Exeter, Devon, United Kingdom, EX2 5DW
        • Royal Devon and Exeter Hospital
      • Plymouth, Devon, United Kingdom, PLG8BX
        • Plymouth Diabetes Clinical Research Unit
    • North Yorkshire
      • Harrogate, North Yorkshire, United Kingdom, HG2 7SX
        • Harrogate and District NHS Foundation Trust
    • UK
      • Bristol, UK, United Kingdom, BS10 5NB
        • University of Bristol
  • United States
    • California
      • Los Angeles, California, United States, 90027
        • Children's Hospital Los Angeles
      • San Francisco, California, United States, 94143
        • University of California - San Francisco
      • Stanford, California, United States, 94305
        • Stanford University
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Barbara Davis Center
    • Connecticut
      • New Haven, Connecticut, United States, 06519
        • Yale University School Of Medicine
    • Florida
      • Gainesville, Florida, United States, 32610
        • University of Florida
      • Miami, Florida, United States, 33136
        • University of Miami
      • Tampa, Florida, United States, 33612
        • USF Diabetes Center
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Emory Children's Center
    • Idaho
      • Boise, Idaho, United States, 83702
        • St. Luke's Humphreys Diabetes Center
      • Idaho Falls, Idaho, United States, 83404
        • Rocky Mountain Clinical Research
    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University - Riley Hospital for Children
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa
    • Kentucky
      • Lexington, Kentucky, United States, 40504
        • University of Kentucky/UK Healthcare
      • Louisville, Kentucky, United States, 40202
        • University of Louisville Pediatric Endocrinology
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Joslin Diabetes Center
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan Health System
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • The Children's Mercy Hospital
    • Nevada
      • Las Vegas, Nevada, United States, 89148
        • Palm Research Center, Inc.
    • New York
      • Buffalo, New York, United States, 14203
        • UBMD Pediatrics
      • New York, New York, United States, 10032
        • Columbia University
      • Syracuse, New York, United States, 13210
        • Joslin Center at SUNY Upstate Medical University
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic Foundation
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • The University of Oklahoma
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104-4399
        • Childrens Hospital Of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15224
        • University of Pittsburgh
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Endocrinology Specialist / Greenville Health System
      • Greenville, South Carolina, United States, 29615
        • GHS - Pediatric Endocrinology
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57105
        • Sanford Children's Specialty Clinic
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt Eskind Diabetes Clinic
    • Texas
      • Dallas, Texas, United States, 75390
        • University of Texas Southwestern
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • University of Utah
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • University of Virginia Health System
    • Washington
      • Seattle, Washington, United States, 98101
        • Benaroya Research Institute
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Medical College of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Participant in TrialNet Pathway to Prevention Study (TN01)
  2. Age 3 years or greater at the time of randomization
  3. Willing to provide informed consent
  4. Normal glucose tolerance by OGTT within 7 weeks (no more than 52 days) of baseline
  5. Two or more diabetes-related autoantibodies present on two separate samples
  6. Weight of 12 kg or greater at screening
  7. If a female participant with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing prior to randomization and at each study visit
  8. Anticipated ability to swallow study medication.

Exclusion Criteria:

  1. Abnormal Glucose Tolerance or Diabetes
  2. History of treatment with insulin or other diabetes therapies
  3. Ongoing use of medications known to influence glucose tolerance
  4. Ongoing or anticipated future use of medications known to have untoward interactions with hydroxychloroquine
  5. Known hypersensitivity to 4-aminoquinoline compounds
  6. G6PD deficiency
  7. History of retinopathy
  8. Have an active infection at time of randomization
  9. Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection
  10. Deemed unlikely or unable to comply with the protocol or have any complicating medical issues, including prolonged QT interval, a disease previously or likely in the future to require immunosuppression, or abnormal clinical laboratory results that interfere with study conduct or cause increased risk.
  11. Deemed unlikely or unable to comply with the protocol or have any complicating medical issues, including prolonged QT interval, a disease previously or likely in the future to require immunosuppression, or abnormal clinical laboratory results that interfere with study conduct or cause increased risk.
  12. Be pregnant or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hydroxychloroquine
Hydroxychloroquine compound for oral use
Drug: Hydroxychloroquine
Hydroxychloroquine for oral administration, dosed by weight
Other Names:
  • Plaquenil
Placebo Comparator: Placebo
Placebo tablet matching active drug
Drug: Placebo
Placebo tablet identical to active drug
Other Names:
  • Inactive Drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes
Time Frame: Glucose tolerance is measured every 6 months for up to 4 years
The primary outcome is the time in months from random treatment assignment to the development of confirmed abnormal glucose tolerance or clinical diabetes.
Glucose tolerance is measured every 6 months for up to 4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborators

Juvenile Diabetes Research Foundation

Investigators

  • Study Chair: Carla Greenbaum, MD, Type 1 Diabetes TrialNet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2018

Primary Completion (Actual)

October 27, 2022

Study Completion (Actual)

October 31, 2022

Study Registration Dates

First Submitted

January 24, 2018

First Submitted That Met QC Criteria

February 8, 2018

First Posted (Actual)

February 12, 2018

Study Record Updates

Last Update Posted (Actual)

April 9, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hydroxychloroquine
  • UC4DK117009 (U.S. NIH Grant/Contract)
  • UC4DK106993 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type1 Diabetes Mellitus

Clinical Trials on Hydroxychloroquine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe